Global Hunter Securities Starts Trius Therapeutics (TSRX) at Buy; Key Torezolid Phase III Data in 1Q12
Tweet
Share
E-mailGet Alerts TSRX Hot Sheet
Price: $13.63 --0%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Global Hunter Securities initiates coverage on Trius Therapeutics (NASDAQ: TSRX) with a Buy. PT $11.
Global analyst said, "TSRX is an emerging, under-covered name in the antibiotics space. We believe the company's lead program, torezolid phosphate, represents a potentially important new treatment for acute bacterial skin and skin structure infections (ABSSSI). The company is currently conducting a phase III trial in ABSSSI under an SPA from the FDA. Top-line data, expected in 1Q12, if successful, could be an important catalyst for shares. The company is also planning to initiate a second phase III trial of torezolid in 2H11 that will explore an IV-to-oral step-down regimen. This trial could position torezolid as a key option for patients transitioning from hospital to outpatient settings. Torezolid is unpartnered, and we expect the company to enter a partnership agreement, potentially ahead of the IV/oral phase III trial. A partnership announcement, receipt of an SPA, initiation of the second phase III trial, and data from the ongoing phase III ABSSSI trial are all potentially meaningful 12-18 month catalysts for TSRX shares."
For more ratings news on Trius Therapeutics click here and for the rating history of Trius Therapeutics click here.
Shares of Trius Therapeutics closed at $8.09 yesterday.
Global analyst said, "TSRX is an emerging, under-covered name in the antibiotics space. We believe the company's lead program, torezolid phosphate, represents a potentially important new treatment for acute bacterial skin and skin structure infections (ABSSSI). The company is currently conducting a phase III trial in ABSSSI under an SPA from the FDA. Top-line data, expected in 1Q12, if successful, could be an important catalyst for shares. The company is also planning to initiate a second phase III trial of torezolid in 2H11 that will explore an IV-to-oral step-down regimen. This trial could position torezolid as a key option for patients transitioning from hospital to outpatient settings. Torezolid is unpartnered, and we expect the company to enter a partnership agreement, potentially ahead of the IV/oral phase III trial. A partnership announcement, receipt of an SPA, initiation of the second phase III trial, and data from the ongoing phase III ABSSSI trial are all potentially meaningful 12-18 month catalysts for TSRX shares."
For more ratings news on Trius Therapeutics click here and for the rating history of Trius Therapeutics click here.
Shares of Trius Therapeutics closed at $8.09 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- Lake Street Starts RF Industries Ltd. (RFIL) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
